CAR T therapies have transformed treatment options for some blood cancers. They have also exposed one of cell therapy's biggest practical limitations: time.
Most approved CAR T treatments are manufactured individually from a patient's own immune cells, a process that can take weeks. For patients with aggressive or advanced disease, that delay can be significant.
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA)'s azer-cel program is designed to address that limitation through an off-the-shelf approach.
Azer-cel is an allogeneic, or donor-derived, CAR T therapy targeting CD19, a protein found on many B-cell cancers. Unlike traditional autologous CAR T treatments, it is manufactured from healthy donor cells and stored ready for use, allowing treatment to be delivered more quickly.
That approach received a regulatory boost today, with the US Food and Drug Administration (FDA) granting Fast Track Designation to azer-cel for two blood cancer indications: relapsed or refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) and relapsed or refractory marginal zone lymphoma (MZL).
The designation provides a clearer pathway through the development process, giving Imugene more frequent engagement with the FDA, access to rolling review of submissions and potential eligibility for Accelerated Approval and Priority Review if future data support it.
More importantly, it arrives as clinical data from azer-cel continues to attract attention in a competitive CAR T landscape.
A different approach to CAR T
Azer-cel is an allogeneic, or donor-derived, CAR T therapy targeting CD19, a protein found on many B-cell cancers.
Unlike traditional autologous CAR T treatments, which are manufactured individually for each patient, azer-cel is produced from healthy donor cells and stored ready for use.
Imugene argues that approach could overcome one of the biggest bottlenecks in cellular therapy.
Current autologous CAR T products typically require three to six weeks between collection of a patient's cells and delivery of treatment. Azer-cel is designed as an "off-the-shelf" product that can be administered within days.
That potential advantage has become increasingly important as companies look for ways to make cell therapies more accessible and easier to deliver.
The FDA's Fast Track Designation comes as Imugene continues to build clinical evidence for the program.
Clinical data driving the story
The FDA's decision was supported by data from Imugene's ongoing Phase 1b trial.
In CLL/SLL, the company reported a 100% overall response rate in CAR T-naive patients who had received a median of three or more prior lines of therapy, results that helped generate significant interest when presented at the American Society of Clinical Oncology (ASCO) annual meeting last week.
The company has also been expanding the study into new patient cohorts, including combinations with Bruton tyrosine kinase inhibitors (BTKi), as it seeks to determine where azer-cel may fit within existing treatment pathways.
The newly disclosed data in marginal zone lymphoma may be equally notable.
Updated results reported after the ASCO data cut-off showed an 83% overall response rate, with five of six evaluable patients responding and four achieving complete responses. Patients in that cohort had received a median of two or more prior lines of therapy.
While the patient numbers remain small, the results were strong enough to help secure Fast Track Designation in both indications.
Imugene managing director and chief executive officer Leslie Chong said the designation reflected "the meaningful clinical activity we are seeing with azer-cel across multiple B-cell malignancies".
"For patients who have exhausted standard treatment options in these indications, we believe azer-cel represents a genuinely promising approach, and this designation will support closer engagement with the FDA as we advance the program," Chong said.
The next challenge
Fast Track Designation does not change the remaining development work. Imugene still needs to generate larger datasets, advance discussions with regulators and ultimately demonstrate that azer-cel can produce durable responses in broader patient populations.
But the FDA's decision provides another signal that regulators see sufficient potential in the program to support an accelerated development pathway.
The focus now shifts back to the clinic, where future data will determine whether azer-cel can build on the early response rates reported to date.